EP1175246A4 - UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS - Google Patents
UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORSInfo
- Publication number
- EP1175246A4 EP1175246A4 EP00916511A EP00916511A EP1175246A4 EP 1175246 A4 EP1175246 A4 EP 1175246A4 EP 00916511 A EP00916511 A EP 00916511A EP 00916511 A EP00916511 A EP 00916511A EP 1175246 A4 EP1175246 A4 EP 1175246A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- upregulation
- hmg
- nitric oxide
- endothelial cell
- coa reductase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27344599A | 1999-03-19 | 1999-03-19 | |
US273445 | 1999-03-19 | ||
PCT/US2000/007221 WO2000056403A1 (en) | 1999-03-19 | 2000-03-17 | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1175246A1 EP1175246A1 (en) | 2002-01-30 |
EP1175246A4 true EP1175246A4 (en) | 2004-12-15 |
Family
ID=23043964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00916511A Withdrawn EP1175246A4 (en) | 1999-03-19 | 2000-03-17 | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1175246A4 (en) |
JP (1) | JP2003511347A (en) |
AU (1) | AU3760300A (en) |
CA (1) | CA2368187A1 (en) |
WO (1) | WO2000056403A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239172B1 (en) | 1997-04-10 | 2001-05-29 | Nitrosystems, Inc. | Formulations for treating disease and methods of using same |
US5968983A (en) | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
US6425881B1 (en) | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
AU4013900A (en) | 1999-03-19 | 2000-10-09 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
WO2002062300A2 (en) * | 2001-02-07 | 2002-08-15 | The Mclean Hospital Corporation | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
DE10257360A1 (en) * | 2002-12-09 | 2004-07-08 | Fresenius Kabi Deutschland Gmbh | Gastrointestinally administrable formulation and its use |
US9345671B2 (en) | 2003-04-28 | 2016-05-24 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
WO2004096276A1 (en) | 2003-04-28 | 2004-11-11 | Sankyo Company, Limited | Sugar intake-ability enhancer |
DE10330768A1 (en) * | 2003-07-07 | 2005-02-24 | bitop Aktiengesellschaft für biotechnische Optimierung | Use of osmolytes obtained from extremophilic bacteria for the preparation of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases, and an inhalation device containing osmolyte as an active ingredient |
CA2545584C (en) | 2003-11-17 | 2012-10-23 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of metabolic disorders |
EP1729761A4 (en) * | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | Cadasil treatment with cholinesterase inhibitors |
TW200612896A (en) * | 2004-09-21 | 2006-05-01 | Sankyo Co | Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione |
JP4949661B2 (en) * | 2004-09-21 | 2012-06-13 | 第一三共株式会社 | Pharmaceutical composition containing HMG-CoA reductase inhibitor and glutathione |
US7893050B2 (en) | 2005-10-26 | 2011-02-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
WO2008036846A2 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
US20100174075A1 (en) * | 2007-06-25 | 2010-07-08 | Nicox S.A. | Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US20200253976A1 (en) * | 2017-09-28 | 2020-08-13 | University Of Massachusetts | Endothelial Facilitation in Neurodegerative Diseases by Cerebral Blood Flow Enhancement |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671171A1 (en) * | 1994-01-18 | 1995-09-13 | Bristol-Myers Squibb Company | Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events |
WO1999018952A1 (en) * | 1997-10-14 | 1999-04-22 | Brigham & Women's Hospital, Inc. | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
-
2000
- 2000-03-17 WO PCT/US2000/007221 patent/WO2000056403A1/en not_active Application Discontinuation
- 2000-03-17 CA CA002368187A patent/CA2368187A1/en not_active Abandoned
- 2000-03-17 AU AU37603/00A patent/AU3760300A/en not_active Abandoned
- 2000-03-17 EP EP00916511A patent/EP1175246A4/en not_active Withdrawn
- 2000-03-17 JP JP2000606302A patent/JP2003511347A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671171A1 (en) * | 1994-01-18 | 1995-09-13 | Bristol-Myers Squibb Company | Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events |
WO1999018952A1 (en) * | 1997-10-14 | 1999-04-22 | Brigham & Women's Hospital, Inc. | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
Non-Patent Citations (4)
Title |
---|
BOEGER RAINER H ET AL: "Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin", CIRCULATION, vol. 96, no. 4, 1997, pages 1282 - 1290, XP002302014, ISSN: 0009-7322 * |
ENDRES ET AL: "stroke protection by HMG-CoA reductase inhibitors mediated by endothelial nitric oxide synthase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 15, 1 July 1998 (1998-07-01), pages 8880 - 8885, XP002091890, ISSN: 0027-8424 * |
LAUFS ET AL: "inhibition of HMG-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 50, 12 December 1997 (1997-12-12), pages 31725 - 31729, XP002091893, ISSN: 0021-9258 * |
See also references of WO0056403A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000056403A1 (en) | 2000-09-28 |
CA2368187A1 (en) | 2000-09-28 |
JP2003511347A (en) | 2003-03-25 |
EP1175246A1 (en) | 2002-01-30 |
AU3760300A (en) | 2000-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1175246A4 (en) | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS | |
AU3107599A (en) | Upregulation of type iii endothelial cell nitric oxide synthase by (rho) gtpase function inhibitors | |
IL145364A0 (en) | Aminopyrimidines as sorbitol dehydrogenase inhibitors | |
PL359820A1 (en) | Hmg-coa reductase inhibitors and method | |
HK1050521A1 (en) | Amidino compounds useful as nitric oxide synthase inhibitors | |
GB0031179D0 (en) | Nitric oxide synthase inhibitors | |
AU2001293373A1 (en) | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | |
AU2001266696A1 (en) | Compounds for targeting endothelial cells | |
AU2002222252A1 (en) | Nitric oxide synthase inhibitor phosphate salt | |
NO20033635D0 (en) | Pyrimidine derivatives for cell proliferation inhibition | |
HUP0401052A3 (en) | Dna-pk inhibitors | |
AU5170900A (en) | Cell proliferation inhibitors | |
AU6909300A (en) | Substituted ureas as cell adhesion inhibitors | |
EP1684754A4 (en) | Hmg-coa reductase inhibitors and method | |
PL355099A1 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors | |
AU6381701A (en) | Bisamidino compounds as nhe-3 inhibitors | |
EP1286702A4 (en) | HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS | |
HK1047434B (en) | Thienopyrimidines as phosphodiesterase inhibitors | |
AU2003272719A1 (en) | Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents | |
AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
AU2003302588A1 (en) | Phosphodiesterase 10a inhibitors | |
MXPA03002858A (en) | Amorphous form of cell cycle inhibitor. | |
AU2001282746A1 (en) | Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors | |
AU2002224550A1 (en) | Corrosion inhibitors | |
PL336853A1 (en) | Derivatives of amidine as inhibitors of nitrogen oxide synthase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011017 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOSKOWITZ, MICHAEL, A. Inventor name: ENDRES, MATTHIAS Inventor name: LAUFS, ULRICH Inventor name: LIAO, JAMES, K. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE GENERAL HOSPITAL CORPORATION Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041104 |
|
17Q | First examination report despatched |
Effective date: 20061011 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061003 |